CareLit · DOI-Nachweis · Aktuelle Neurologie
Cognitive effects of a prolonged-release formulation of galantamine (PRC) in patients with Alzheimer's disease – An open-label phase-IIIb-study
DOI 10.1055/s-2007-987946
Bibliografische Angaben
Nachweis in CareLit
Autor:innenHJ Möller, M Gerwe, B Ibach, J Czekalla
ZeitschriftAktuelle Neurologie
Ausgabe09/2007
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Randomized controlled clinical trials have demonstrated the efficacy of galantamine-PRC in the treatment of Alzheimer's disease (AD)-patients. Objectives of this clinical trial were to further study the overall effect of galantamine-PRC on cognition and function in patients with AD. Methods: Open-label, multi-center clinical trial (GAL-DEM-3002). Patients with mild to moderate AD (NINCDS-ADRDA criteria)…
Zitieren
Zitierempfehlung
HJ Möller, M Gerwe, B Ibach, J Czekalla (2007) Cognitive effects of a prolonged-release formulation of galantamine (PRC) in patients with Alzheimer's disease – An open-label phase-IIIb-study. Aktuelle Neurologie (09). https://doi.org/10.1055/s-2007-987946
Mit CareLit weiterarbeiten